acute kidney injury (aki) recognition and management in ......312 studies, 152 using kdigo-aki, 50...
TRANSCRIPT
1
Acute Kidney Injury (AKI)Recognition and Management in General Pediatrics
Samhar Al-Akash, MD
Pediatric NephrologyDriscoll Children’s Hospital
Corpus Christi, TXUSA
26th Annual Pediatric Conference Driscoll Health System
Corpus Christi, TXJuly 26-27, 2019
Disclosures
• No financial conflicts to disclose
Objectives
� Definitions and classification of AKI� Significance / Epidemiology / Impact of AKI� Risk factors for AKI� Etiology and pathophysiology of AKI (nephrotoxic)� AKI and CKD� Biomarkers - Early recognition and diagnosis of AKI � Management guidelines and best practices
2
AKI - Definition
� Abrupt loss of kidney function that results in:� Decline in GFR (serum creatinine) � Retention of urea and other nitrogenous wasted
products (BUN)� Dysregulation of extracellular volume and electrolytes
(volume, Potassium, acid-base)
� Formerly known as acute renal failure:� Did not reflect a continuum of manifestations� Late recognition
Definition of Acute Kidney InjuryRIFLE
R Bellomo et al, Critical Care 2004; 8: R204-R212Z Ricci et al, Kidney Int 2008; 73: 538-546
Definition of Acute Kidney InjurypRIFLE
Z Ricci et al, Kidney Int 2008; 73: 538-546
3
Definition of Acute Kidney InjurypRIFLE
Z Ricci et al, Kidney Int 2008; 73: 538-546
� Example 1:� 5-year-old � SCr 0.4 on admission� SCr 0.6 on day 2 � CrCl is lower by 50%
� Injury (AKI)
� Example 2:� 2-year-old � SCr 0.5 on day 3 (from 0.3) � CrCl is lower by 67%� Injury (AKI)
� Urine output 0.2 ml/kg/hour – Failure
Definition of Acute Kidney InjuryAKIN
D Cruz et al, Critical Care 2009; 13: 211-220
Definition of Acute Kidney Injury
KDIGO, Kidney Int 2012; S2: 19-36
4
Definition of Acute Kidney Injury
KDIGO, Kidney Int 2012; S2: 19-36
Worldwide Epidemiology of AKI
P Susantitaphong et al, Clin J Am Soc Nephrol 2013; 8: 1482-1493
312 studies, 152 using KDIGO-AKI, 50 million episodesPooled AKI incidence 21.6% in adults, 33.7% in children
Pooled AKI mortality rates 23.9% in adults, 13.8% in children
Worldwide Epidemiology of Acute Kidney Injury
P Susantitaphong et al, Clin J Am Soc Nephrol 2013; 8: 1482-1493
5
Worldwide Epidemiology of Acute Kidney Injury
P Susantitaphong et al, Clin J Am Soc Nephrol 2013; 8: 1482-1493
Worldwide AKI - Mortality
P Susantitaphong et al, Clin J Am Soc Nephrol 2013; 8: 1482-1493
Worldwide Epidemiology of AKI - KDIGO
E Hoste et al, Nature Rev Nephrol 2018; 14: 607-625
6
Pediatric AKI and Survival (KDIGO) - AWARE
A Kaddourah et al, New Eng J Med 2017; 376:11-20
• AWARE
• N = 4683
• AKI 26.9%• Severe AKI 11%
OR 1.77
AKI Prevalence - ICU
A Kaddourah et al, New Eng J Med 2017; 376:11-20
Epidemiology of AKI - Children
S Sutherland et al, Clin J Am Soc Nephrol 2013: 8: 1661-1669
7
Epidemiology of AKI - Children
S Sutherland et al, Clin J Am Soc Nephrol 2013: 8: 1661-1669
• KID = Kids Inpatient Database.
• All payer, 4121 Hospitals, 44 states
• Analysis of 2009 data
AKI in Children – Mortality and Morbidity
S Sutherland et al, Clin J Am Soc Nephrol 2013: 8: 1661-1669
AKI in Children – Mortality and Morbidity
S Sutherland et al, Clin J Am Soc Nephrol 2013: 8: 1661-1669
8
Mortality/Severe AKI – Who is at greatest risk?
S Sutherland et al, Clin J Am Soc Nephrol 2013: 8: 1661-1669R Basu et al, Lancet Child Adolesc Health 2018; 2(2): 112-120
� Sepsis� Shock� Vasoactive support� Mechanically ventilated� Lower UOP� Malnourished – underweight
� RENAL ANGINA INDEX (RAI) > 8Risk level Description Risk
score
Moderate ICU status 1
High Transplant 3
Very high Mech. vent./inootropes 5
Injury (SCr) Injury (fluid overload) Injury Score
No change < 5% 1
Stage 1 > 5% 2
Stage 2 > 10% 4
Stage 3 > 15% 8
X
Epidemiology of AKI - Children
S Sutherland et al, Clin J Am Soc Nephrol 2013: 8: 1661-1669
Epidemiology of AKI - Children
S Sutherland et al, Clin J Am Soc Nephrol 2013: 8: 1661-1669
9
Pediatric AKI
S Sutherland et al, Clin J Am Soc Nephrol 2015; 10(4): 554-561
• Stanford Lucile-Packard
• 2006-2010
• Observational – EMR enabled
• AKI based only on SCr
Pediatric AKI – Incidence
S Sutherland et al, Clin J Am Soc Nephrol 2015; 10(4): 554-561
S Sutherland et al, Clin J Am Soc Nephrol 2015; 10(4): 554-561
Pediatric AKI – Mortality
10
Pediatric AKI - Mortality
S Sutherland et al, Clin J Am Soc Nephrol 2015; 10(4): 554-561
Acute Kidney Injury - Morbidity
S Sutherland et al, Clin J Am Soc Nephrol 2015; 10(4): 554-561
Acute Kidney Injury - Neonates
J Jetton / D. Askenazi et al, lancet Child Adolesc Health 2018; 1(3): 184-194
11
Acute Kidney Injury - Neonates
J Jetton / D. Askenazi et al, lancet Child Adolesc Health 2018; 1(3): 184-194
Acute Kidney Injury - Neonates
AKI in Non-critically Ill Children
N. Donmez, K. Hyunh, Z. Perez, S. Al-Akash – PAS Toronto May 2018
� Incidence 5%� Driscoll Children’s Hospital:
� Retrospective study 1/1/2016 – 1/1/2017� Using SCr criteria (0.3 increase or > 50% above baseline)� EMR-based inquiry� Exclusions: PICU prior to AKI, < 1 month, transplant, CKD� Results:
� AKI incidence 6.2% (114 of 1844 admissions)� Median eCrCl (Schwartz) 49 vs. 133 ml/min (P < 0.0001)� Only 24% had a diagnosis of AKI in the chart� With nephrology consult 62.5% documented AKI in the chart
(OR 9.9, p <0.0001)� 67% of patients with AKI had nephrotoxic exposure (1-28%, 2 or
more 39%) (NSAID’s 40%, Vancomycin 36%)� Nephrotoxic exposure increased hospital LOS 3 days on average
12
Aminoglycoside-associated AKI in Children
1M Zappitelli et al, Nephrol Dial Transplant 2011; 26(1): 144-1502J Saban et al, Pediatr Nephrol 2017; 32(1): 173-179
� Aminoglycoside (AG) toxicity in 20% (AKIN) and 33% (pRIFLE) of children (Gentamicin 88%) 1
� Exposure (median duration of AG therapy) is associated with increased severity of AKI2:� Stage 1 – 98 hours� Stage 2 – 231 hours� Stage 3 – 111 hours
� Prior exposure to AG was associated with higher risk of AKI2:� 1.5 + 1.8 episodes (AKI) vs 0.9 + 1.6 (no-AKI)� Tobramycin, younger age, # of AG treatment days, Hem/Onc
Economic Impact of AKI
Acute Kidney Injury (AKI) &Chronic kidney Disease (CKD)
13
AKI – Natural History
J Cerda et al, Clin J Am Soc Neprol 2008; 3: 881-886
AKI – Natural History
L Chawla et al, Kdiney Int 2011; 79: 1361-1369
CKD after AKI
S Mehta et al, BMC Nephrol 2018; 19: 91-101
14
AKI Increases Risk for CKD
L Forni et al, Intensive Care Med 2017; 43: 855-866
AKI and Survival
O Rewa et al, Nature Rev Nephrol 2014; 10: 193-207
AKI Increases Risk for CKD
L Forni et al, Intensive Care Med 2017; 43: 855-866
15
AKI Increases Risk for CKD
CKD After AKI in Developed Counties
S. Goldstein et al, Clin J Am Soc Nephrol 2013; 8(3): 476-483
CKD after AKI
C Mammen et al, Am J Kidney Dis 2012; 59(4): 523-530
� Critically-ill children:� Patients admitted to PICU 2006-2008 with AKI (n = 126)� Survivors assessed at 1, 2, 3 years� AKIN classification (stages: 1 = 35%, 2 = 37%, 3 = 28%)
� CKD: microalbuminuria and/or eGFR < 60 ml/min� Overall CKD 10%:
� stage 1-4.5%, 2-10.6%, 3-17.1%
� At risk for CKD: eGFR 60-90 ml/min, HTN, or eGFR > 150 ml/min� 46.8% overall
16
CKD after AKI
S Hui-Stickle et al, Am J Kidney Dis 2015; 45(1): 96D Askenazi et al Kidney Int 2006; 69(1): 184
� Critically-ill children:� Patients admitted 1998-2001� 254 AKI episodes in 248 children� Cause of AKI: renal ischemia (21%), nephrotoxic (16%),
sepsis (11%), renal disease (17%)
� Overall survival 70%
� At discharge - 34% had CKD or were dialysis dependent � At 3-5 year FU:
� CKD in 60% (microalbuminuria, proteinuria, HTN, decreased GFR)
� ESRD in 9%
AKI – Children at Risk
� Critically-ill children:� Post-cardiac surgery
� Longer bypass times� Younger age and lower weight� Lower pre-operative creatinine� Mechanical ventilation
� Non-cardiac (others):� Younger and older ages� Mechanical ventilation� Higher PRISM score � Hypovolemia� Coagulopathy� Vasopressor support� Nephrotoxic medications
AKI – Children at Risk
� Non-critically-ill children:� Younger age� Lower birth weight� Lower baseline serum creatinine� Higher Exposure to nephrotoxic medications:
� Higher dose� More frequent dosing � Longer duration of therapy
� Higher number of nephrotoxic medications uses� Aminoglycoside associated AKI:
� Higher exposure� Prior aminoglycoside treatment (especially within prior 30days)� Hem/Onc service� Hypoalbuminemia / hypovolemia� Other nephrotoxic exposure� Neonate
17
AKI - Etiology
P Stephens, Medicine 2007; 35(8): 429-433
Nephrotoxic AKI - Etiology
� Drug-related factors� Patient factors� Kidney factors
Nephrotoxic AKI Risk – Patient Factors
M Perazella , Clin J Am Soc Nephrol 2018; 13(12): 1897-1908
18
Nephrotoxic AKI – Drug Factors
M Perazella , Clin J Am Soc Nephrol 2018; 13(12): 1897-1908
Nephrotoxic AKI – Kidney Factors
M Perazella , Clin J Am Soc Nephrol 2018; 13(12): 1897-1908
Nephrotoxic AKI Risk - Drug
M Perazella , Clin J Am Soc Nephrol 2018; 13(12): 1897-1908
19
AKI – Nephrotoxic Medications
Nephrotoxic AKI
Nephrotoxic AKI
20
BIOMARKERS
Biomarkers in AKI
P Murray et al, Kidney Int 2014; 859(3): 513-521
Biomarkers in AKI
P Murray et al, Kidney Int 2014; 859(3): 513-521
21
Biomarkers in AKI – Serum Creatinine
Bennett et al, Clin J Am Soc Nephrol 2008; 3: 665-673
Biomarkers in AKI
P Murray et al, Kidney Int 2014; 859(3): 513-521
Biomarkers in AKI – NGAL
Bennett et al, Clin J Am Soc Nephrol 2008; 3: 665-673
22
Biomarkers in AKI - Nephrocheck
Biomarkers in AKI
L Forni et al, Kidney Intensive Care Med 2017; 43: 855-866
Biomarkers in AKI
23
Can AKI Be Prevented??
AKI – Prevention
� Identify children at risk
� Correct / prevent hypovolemia:� Early fluid administration / resuscitation� Data supports approach in:
� Rhabdomyolysis, hemoglobinuria� Tumor lysis syndrome� Nephrotoxic medications (acyclovir, aminoglycosides, ampho-B)� Chemotherapy (cisplatin, MTX)� Radiocontrast
� Prevent nephrotoxic AKI:� Frequent monitoring of renal function when used� Frequent monitoring of drug levels� Early dose adjustment, drug class change(Nephrotoxic AKI increases with increased exposure (number of drugs, dose, and duration)
NINJA
Nephrotoxic-Injury Negated by Just-in-time Action
24
NINJA
AKI – Nephrotoxic Medications
AKI – Prevention
� Quality improvement Study:� 1749 patients / 2356 admissions / 3243 nephrotoxic exposure /
170 patient (9.7%) – non-critically ill� Using EMR algorithms to identify at risk patients:
� aminoglycoside x 3 days or more, or � 3 or more nephrotoxic meds for 3 days)
� Nephrotoxic exposure decreased by 38%� AKI incidence decreased by 64%
S Goldstein et al, Kidney Int 2016; 90(1): 212-221
25
Clinical Approach to AKI
Step Evaluation
1. Volume status H&P, weight, UOP, fluid challenge
2. Obstruction? H&P, Foley, renal US
3. Renal function tests Chem panel, PO4, Hgb
4. Probable cause of AKI Evaluate for nephrotoxic exposure, hypovolemia, hypotension, drug levels
5. Urinalysis and microscopy SG, protein, blood, casts, cells, crystals
6. Urinary indices – FENa+ Spot urine for Na+ and Creatinine
7. Further tests Biomarkers, immune workup (GN), imaging, biopsy
Treatment of AKI
Specific Supportive
• Volume resuscitation• Correction of hypotension• Remove obstruction• Remove nephrotoxic agent• Sepsis treatment• Disease-specific therapy (GN,
pyelonephritis) – IMS
• Correction of electrolyte problems (K+, acidosis, PO4, Ca)
• Correction of hypervolemia (should not be an emergency)
• Fluid restriction??? Diuresis??• Nutrition• Correction of anemia• Dialysis (PD, HD, CRRT) – early
initiation in critically-ill• Drug dosing adjustment (for GFR
and for dialysis)
Fluid Overload in AKI
26
Fluid Overload in AKI - Mortality
S Sutherland et al, Am J Kid Dis 2010; 55(2): 316-325
Dialysis in AKI
� When is dialysis indicated?� Fluid� Electrolyte� Other
� Goal of therapy? Supportive:� Provide optimal medications, nutrition, blood products,
electrolyte balance, without worsening fluid overload
� What modality?� Patient factors: Needs, anatomy, access� Center factors: Resources� No modality is better than the other
� How long?� Until kidneys get better
Dialysis in AKI
� Single center retrospective study� AKI post cardiac surgery (n = 480)� AKI within 72 hours:
� 23% in neonates, and 26% in children
� AKI was associated with:� Increased PICU LOS (12 vs 4 days, p < 0.001)� Increased hospital LOS (27 vs 14 days, p < 0.001)� Increased mortality (17.5% vs 3.7%, p < 0.01)
� Dialysis therapy (neonates 16% vs 3.8% in other, p < 0.01)� PD initiation < 24 hours associated with lower mortality vs
PD > 24 hours (25% vs 44%)� CRRT was associated with 28.6% mortality (2/7) (no
mortality in patients started on CRRT < 24 hours)
J Sanchez-De-Toledo et al, Pediatr Cardiol 2016; 37(4): 623-628
27
Management – Follow up after AKI
L Chawla et al, Nature Rev Nephrol 2017; 13(4): 241-257
AKI - Summary
AKI - Conclusion
� AKI is bad:� Increased morbidity and mortality� Increased CKD� Increased cost
� Risk factors for increased mortality and morbidity:� Severity of AKI� Severity of fluid overload� Late initiation of RRT (dialysis)� Patient risk factors
� Nephrotoxic AKI can be prevented
28
THANK YOU